Screener
Upstream Bio, Inc. UPB Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Upstream Bio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 7:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-343417
FAQ
- What is Upstream Bio, Inc.'s cash & equivalents?
- Upstream Bio, Inc. (UPB) reported cash & equivalents of $79.4M in Q2 2026.
- How has Upstream Bio, Inc.'s cash & equivalents changed year-over-year?
- Upstream Bio, Inc.'s cash & equivalents increased by 74.7% year-over-year, from $45.46M to $79.4M.
- What is the long-term trend for Upstream Bio, Inc.'s cash & equivalents?
- Over 2 years (2023 to 2025), Upstream Bio, Inc.'s cash & equivalents has grown at a 98.3% compound annual growth rate (CAGR), from $25.83M to $101.58M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Upstream Bio, Inc.'s cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude